Skip to content

Clinical validation of the NOVEOS immunoassay for allergy diagnostics

Clinical validation of the NOVEOS immunoassay for allergy diagnostics - Clinical validation of the NOVEOS immunoassay

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON51863
Enrollment
326
Registered
2022-04-07
Start date
2023-03-16
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergy hypersensitivity Allergy

Interventions

sIgE bepaling op Noveos

Sponsors

Reinier de Graaf
Lead Sponsor

Eligibility

Age
2 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age > 3 years Suspected food allergy to peanut, cow's milk, chicken egg, nuts, sesame seeds, cod and/or wheat.

Exclusion criteria

Exclusion criteria: Use of anti-IgE injections (Xolair), systemic corticosteroids, or anti-histamines (which should be discontinued three days before performing a skin prik test).

Design outcomes

Primary

MeasureTime frame
sIgE against 12 allergens is determined on the NOVEOS system and compared with the results of the skin prick tests, the clinical diagnosis and sIgE measurements on the standard method (Siemens Immulite).

Secondary

MeasureTime frame
There will be investigated whether the use of biotin supplements leads to different results on the NOVEOS compared to the Immulite. In addition, it will be investigated whether there is less interference of sIgE against CCDs on the NOVEOS.

Countries

Netherlands

Contacts

Public ContactM.R. Batstra

Reinier de Graaf

m.batstra@rdgg.nl0152604526

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Feb 3, 2026